-
公开(公告)号:US09205152B2
公开(公告)日:2015-12-08
申请号:US13863525
申请日:2013-04-16
IPC分类号: A61K36/00 , A61K47/00 , A61K31/05 , B29C47/00 , A61K47/42 , A61K8/02 , A61K8/64 , A61Q17/00 , A61Q19/10 , A01N25/28 , C08K5/00 , C08K5/053 , C08L89/00 , C08K5/09 , C08K5/1515
CPC分类号: A61K47/42 , A01N25/28 , A61K8/0208 , A61K8/645 , A61Q17/005 , A61Q19/10 , C08K5/0016 , C08K5/0025 , C08K5/053 , C08K5/09 , C08K5/1515 , C08L89/00 , A01N25/10 , A01N65/00
摘要: A melt-processed protein composition formed from a protein, plasticizer, and an electrophilic reagent is provided. The electrophilic reagent, for instance, may be selected to undergo a nucleophilic addition reaction with free sulfhydryl and/or thiyl radicals to help minimize the formation of disulfide crosslinking bonds that could otherwise lead to protein aggregation during melt processing. To enhance the degree to which the electrophilic reagent can limit crosslinking, a plasticizer is also employed that helps to mediate the adsorption of the electrophilic reagent into the internal structure of the protein, where it can be more stably retained. Furthermore, the temperature and shear rate employed during melt blending may also be selected to be relatively low to help limit polypeptide dissociation, thereby minimizing the impact of aggregation and embrittlement.
摘要翻译: 提供由蛋白质,增塑剂和亲电试剂形成的熔融加工的蛋白质组合物。 例如,亲电试剂可以选择与游离的巯基和/或硫代基进行亲核加成反应,以帮助最小化二硫键交联键的形成,否则可能在熔融加工过程中导致蛋白质聚集。 为了提高亲电子试剂可以限制交联的程度,还可以使用有助于介导亲电试剂吸附到蛋白质的内部结构中的增塑剂,其中可以更稳定地保留亲和亲水试剂。 此外,熔融共混过程中使用的温度和剪切速率也可以选择为相对较低,以帮助限制多肽解离,从而最小化聚集和脆化的影响。
-
公开(公告)号:US09198973B2
公开(公告)日:2015-12-01
申请号:US13919403
申请日:2013-06-17
CPC分类号: A61K47/48207 , A61K47/595 , C08L79/02 , C08L2203/02
摘要: The present invention is directed to a polymeric compound with a size in a nanometric scale, useful as a biocompatible carrier for the transport and delivery of active agents into a fish, insect, animal, reptile, bird, human, or plant, wherein said polymeric compound comprises PAMAM (polyamidoamine) dendrimers, a spacer molecule, and cafestol, wherein the polymeric compound of the invention comprises a structure of the kind (cafestol-PAMAM derivative)2-spacer molecule. Use of the compound as a biocompatible carrier for transport and delivery of antithrombotic active agents is disclosed. Procedures for obtaining a polymeric compound comprising the activation of cafestol, activation of polyethylene glycol, and formation of cafestol-PAMAM-PEG-PAMAM-cafestol are also disclosed.
摘要翻译: 本发明涉及一种尺寸为纳米级的聚合化合物,其可用作生物相容载体,用于将活性剂转运和递送至鱼,昆虫,动物,爬行动物,鸟,人或植物中,其中所述聚合物 化合物包括PAMAM(聚酰胺胺)树枝状大分子,间隔分子和咖啡豆,其中本发明的高分子化合物包含这种类型的结构(cafestol-PAMAM衍生物)2-间隔物分子。 公开了该化合物作为生物相容载体用于运输和递送抗血栓活性剂的用途。 还公开了用于获得包含活性咖啡醇,聚乙二醇的活化以及咖啡酚-PAMAM-PEG-PAMAM-cafestol的形成的聚合物的方法。
-
公开(公告)号:US09192179B2
公开(公告)日:2015-11-24
申请号:US13502918
申请日:2010-11-11
申请人: Zamzam (Fariba) Roughead , Jalil Benyacoub , Claudia Roessle , Jennifer Rae Mager , Julie Ann Swanson , Norman Alan Greenberg , Douglas Richard Bolster , Clara Lucia Garcia Rodenas , Florence Rochat
发明人: Zamzam (Fariba) Roughead , Jalil Benyacoub , Claudia Roessle , Jennifer Rae Mager , Julie Ann Swanson , Norman Alan Greenberg , Douglas Richard Bolster , Clara Lucia Garcia Rodenas , Florence Rochat
CPC分类号: A23L33/21 , A23L29/244 , A23L29/25 , A23L33/10 , A23L33/40 , A23V2002/00 , A61K31/702 , A61K31/715 , A61K38/28 , A23V2200/324 , A23V2200/306 , A23V2250/5062 , A23V2250/503 , A23V2250/28
摘要: The present disclosure relates to nutritional compositions comprising a fructo-oligosaccharide (FOS) in an amount of 35 to 44% by weight; a polysaccharide that is not a partially hydrolyzed guar gum such as, for example, an arabinogalactan in an amount of 50% to 38% by weight; and inulin in an amount of 12% to 24% by weight. The FOS and the polysaccharide may be present in a weight ratio of about 1:1. More specifically, the FOS and inulin may be present in a weight ratio of about 7:3. Also provided are methods of promoting gut microbiota balance and health. The methods include administering an effective amount of the nutritional composition to patients in need of same.
摘要翻译: 本公开涉及包含35至44重量%的低聚果糖(FOS)的营养组合物; 不是部分水解的瓜尔胶的多糖,例如50-38重量%的阿拉伯半乳聚糖; 和菊糖,其量为12重量%至24重量%。 FOS和多糖可以以约1:1的重量比存在。 更具体地说,FOS和菊粉可以以约7:3的重量比存在。 还提供了促进肠道微生物平衡和健康的方法。 所述方法包括向有需要的患者施用有效量的营养组合物。
-
公开(公告)号:US09173942B2
公开(公告)日:2015-11-03
申请号:US13901830
申请日:2013-05-24
发明人: Giorgio Calderari , Daniele Bonadeo , Roberta Cannella , Alberto Macciocchi , Andrew Miksztal , Thomas Malefyt , Kathleen M Lee
IPC分类号: A01N43/52 , A61K47/26 , A61K47/18 , A61K47/12 , A61K47/00 , A61K31/473 , A61K47/02 , A61K9/00 , B65B7/16 , B65B55/02
CPC分类号: A61K9/08 , A61K9/0019 , A61K9/0095 , A61K31/473 , A61K47/00 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , B65B7/16 , B65B55/02
摘要: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
-
公开(公告)号:US09173830B1
公开(公告)日:2015-11-03
申请号:US14260775
申请日:2014-04-24
申请人: Avon Products, Inc.
IPC分类号: A61Q17/04 , A61K8/02 , A61K33/04 , A61K47/00 , A61K8/88 , A61K8/25 , A61K8/23 , A61K8/37 , A61K8/35 , A61K8/40
CPC分类号: A61K8/88 , A61K8/0241 , A61K8/025 , A61K8/0279 , A61K8/19 , A61K8/23 , A61K8/25 , A61K8/35 , A61K8/37 , A61K8/40 , A61K8/891 , A61K2800/262 , A61K2800/43 , A61K2800/54 , A61K2800/591 , A61K2800/614 , A61K2800/624 , A61K2800/652 , A61K2800/654 , A61Q17/04
摘要: Compositions comprising an organic sunscreen in combination with (i) nylon particles, (ii) silica particles, and (iii) barium sulfate particles provide an improvement in SPF as compared to an otherwise identical composition lacking any one of the three ingredients (i)-(iii). The compositions advantageously provide high diffuse transmittance, giving a natural look to the skin.
摘要翻译: 与(i)尼龙颗粒,(ii)二氧化硅颗粒和(iii)硫酸钡颗粒组合的有机防晒剂的组合物与缺少三种成分(i)中的任何一种的其它相同组合物相比,提供了SPF的改进 - (iii)。 所述组合物有利地提供高漫射透射率,给予皮肤自然的外观。
-
公开(公告)号:US09149542B2
公开(公告)日:2015-10-06
申请号:US13807683
申请日:2011-06-30
申请人: Yong Song Gho , Su Chul Jang , Yoon Keun Kim , Oh Youn Kim
发明人: Yong Song Gho , Su Chul Jang , Yoon Keun Kim , Oh Youn Kim
IPC分类号: A61K47/48 , A61K49/00 , A61K47/46 , A61K9/50 , A61K47/40 , A61K47/00 , A61K47/10 , A61K9/127 , A61K39/39 , A61K38/16 , A61K38/18 , A61K38/20 , A61K38/21 , A61K45/06 , A61K39/02 , C07K14/71 , B82Y5/00 , A61K39/00
CPC分类号: A61K47/48838 , A61K9/127 , A61K9/5063 , A61K38/162 , A61K38/1825 , A61K38/1866 , A61K38/20 , A61K38/21 , A61K39/0011 , A61K39/02 , A61K39/39 , A61K45/06 , A61K47/00 , A61K47/10 , A61K47/40 , A61K47/46 , A61K47/6917 , A61K49/0017 , A61K49/0045 , A61K49/0097 , A61K2039/55555 , B82Y5/00 , C07K14/71 , C07K2319/00 , Y10S977/773
摘要: The present application relates to microvesicles derived from a protoplast which is a bacterial, arhaea, fungal or plant cell or the like from which a cell wall is removed. The microvesicles derived from a protoplast enables free loading of a material necessary for diagnosis, treatment, vaccine, target induction, cell membrane fusion with a target cell, reduction of in vivo and in vitro side effects, stability improvement, and the like, and allows the therapeutic material, the diagnostic material and/or the vaccine material to be delivered specifically to a specific tissue or cell.
-
公开(公告)号:US09127267B2
公开(公告)日:2015-09-08
申请号:US13674283
申请日:2012-11-12
发明人: Scott Banta , Mark A. Blenner , Ian Wheeldon , Kevin Dooley
IPC分类号: A01N25/00 , A61K47/00 , A61K38/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00 , A61K38/04 , C12N9/88 , A61L27/22 , A61L27/50 , A61L27/52 , A61L27/54 , A61L15/32 , A61L15/42 , A61L15/44 , A61L15/46 , A61L15/60
CPC分类号: C12N9/88 , A61L15/32 , A61L15/42 , A61L15/44 , A61L15/46 , A61L15/60 , A61L27/227 , A61L27/50 , A61L27/52 , A61L27/54 , A61L2400/06 , C12Y406/01001 , C08L89/00
摘要: In one aspect, the invention relates to a peptide that forms a calcium-dependent hydrogel using a rationally engineered beta roll peptide. In the absence of calcium, the peptide is intrinsically disordered. Upon addition of calcium, the peptide forms a corkscrew-like structure. In one embodiment, one face of the beta roll is mutated to comprise leucine residues. In some embodiments, a leucine zipper forming helical domain to the engineered beta roll forms hydrogels by physical cross-linking in calcium rich environments.
摘要翻译: 在一个方面,本发明涉及使用合理工程化的β卷肽形成钙依赖性水凝胶的肽。 在不存在钙的情况下,肽本质上是无序的。 加入钙后,肽形成螺塞状结构。 在一个实施方案中,β卷的一个表面被突变以包含亮氨酸残基。 在一些实施方案中,形成螺旋结构域的亮氨酸拉链与工程化的β型辊在富含钙的环境中通过物理交联形成水凝胶。
-
公开(公告)号:US09101662B2
公开(公告)日:2015-08-11
申请号:US14045528
申请日:2013-10-03
发明人: Dov Tamarkin , Meir Eini , Doron Friedman , Tal Berman , David Schuz
IPC分类号: A61K9/00 , A61K47/00 , A61K47/12 , A61K31/573 , A61K31/593 , A61K31/341 , A61K31/167 , A61K47/18 , A61K9/12 , A61K31/375 , A61K47/26 , A61K47/32
CPC分类号: A61K47/12 , A61K9/0014 , A61K9/0031 , A61K9/0034 , A61K9/0043 , A61K9/0046 , A61K9/0048 , A61K9/0056 , A61K9/122 , A61K31/167 , A61K31/341 , A61K31/375 , A61K31/56 , A61K31/573 , A61K31/593 , A61K47/18 , A61K47/183 , A61K47/26 , A61K47/32
摘要: The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless composition and foam.
摘要翻译: 本发明涉及作为载体的无水组合物和泡沫,其中活性药物或化妆品在添加时稳定或稳定化或其不稳定性受到调节剂的存在的阻碍。 药物或化妆品组合物和泡沫体包括:无水溶剂,调节剂和一种或多种活性药物或化妆品。 本发明还涉及给予无水组合物和泡沫的治疗方法。
-
79.
公开(公告)号:US09095568B2
公开(公告)日:2015-08-04
申请号:US12680548
申请日:2008-09-26
CPC分类号: A61K47/48907 , A61K31/575 , A61K39/07 , A61K39/39 , A61K47/6455 , A61K47/6935 , A61K2039/55555 , A61K2039/6093 , C08G63/91
摘要: Polyelectrolyte nanoparticle compositions for biomedical applications are provided comprising at least two carrier domains comprising multivalent ionic domains and an agent exhibiting biological activity when contained within the nanoparticle or on the nanoparticle surface. The multivalent ionic domains may be contained in two separate molecules or in separate but linked domains of a single molecule. The nanoparticle optionally can further comprise an exposed targeting ligand and/or protective surface. The nanoparticle can be contacted to cells or administered directly to an animal for biomedical applications including therapeutics and immune response. The nanoparticle may alternatively be comprised of a carrier material capable of delivering various medically important antigens as vaccine.
摘要翻译: 提供了用于生物医学应用的聚电解质纳米颗粒组合物,其包含至少两个包含多价离子结构域的载体结构域和当纳入纳米颗粒或纳米颗粒表面时含有生物活性的试剂。 多价离子结构域可以包含在两个分开的分子中或者在单个分子的单独但连接的结构域中。 纳米颗粒任选地还可以包含暴露的靶向配体和/或保护表面。 纳米颗粒可以与细胞接触或直接施用于动物用于生物医学应用,包括治疗学和免疫应答。 纳米颗粒可以替代地由能够递送各种医学上重要的抗原作为疫苗的载体材料组成。
-
公开(公告)号:US09089529B2
公开(公告)日:2015-07-28
申请号:US13660957
申请日:2012-10-25
IPC分类号: A61K9/19 , A61K39/395 , A61K47/26 , A61K47/00 , A61K31/195 , C07K16/18 , A61K31/198 , A61K31/454 , A61K31/69 , A61K38/07
CPC分类号: A61K9/19 , A61K31/195 , A61K31/198 , A61K31/454 , A61K31/69 , A61K38/07 , A61K39/3955 , A61K39/39591 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K2317/14 , C07K2317/24 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要: Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.
摘要翻译: 用于预防或治疗淀粉样变性的抗体制剂和方法,包括AA淀粉样变性和AL淀粉样变性。
-
-
-
-
-
-
-
-
-